Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Inotiv, Inc.v330984_ex99-1.htm
EX-10.1 - EXHIBIT 10.1 - Inotiv, Inc.v330984_ex10-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): December 21, 2012

 

 

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

 

Indiana   0-23357   35-1345024
(State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

 

2701 KENT AVENUE

WEST LAFAYETTE, INDIANA

 

 

47906-1382

(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (765) 463-4527

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

 

 
 

 

 

The information provided in Item 2.02 and Item 9.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 and Item 9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

 

Item 1.01 Entry in a Material Definitive Agreement

 

On December 21, 2012, Bioanalytical Systems, Inc. (the "Company") and Regions Bank (“Regions”) entered into the Amended and Restated Sixth Amendment to Loan Agreement (“Amendment”) . The Amendment became effective as of November 1, 2012 and extended the Regions term loan maturity date to October 31, 2013.

 

The foregoing discussion of the Amendment is entirely qualified by reference to the text of the Amendment, which is attached as Exhibit 10.1, and incorporated herein by this reference.

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On December 27, 2012, Bioanalytical Systems, Inc. issued a press release announcing results for the three and twelve months of fiscal 2012, ending September 30, 2012. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

  

Item 9.01. Financial Statements and Exhibits.

 

(d)  Exhibits

 

10.1Amended and Restated Sixth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed on December 21, 2012.

 

99.1Bioanalytical Systems, Inc. press release, issued December 27, 2012.

 

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  Bioanalytical Systems, Inc.
   
Date: December 27, 2012 By:  /s/ Jacqueline M. Lemke
    Jacqueline M. Lemke
Interim President and Chief Executive Officer and Chief Financial Officer and Vice President—Finance

 

 

 
 

 

 

Exhibit Index 

 

Exhibit No.   Description
     
10.1   Amended and Restated Sixth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed on December 21, 2012.
     
99.1   Bioanalytical Systems, Inc. press release, issued December 27, 2012.